Molecular profiling and clinical outcome of high-grade serous ovarian cancer presenting with low- versus high-volume ascites

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Feigenberg, Tomer ^a,b   Clarke, Blaise ^c,d   Virtanen, Carl ^d   Plotkin, Anna ^b,c   Letarte, Michelle ^e   Rosen, Barry ^a,f   Bernardini, Marcus Q ^a,f   Kollara, Alexandra ^g   Brown, Theodore J ^g   Murphy, K Joan ^a,f  

^a UNIVERSITY OF TORONTO   (Canada)

^b CREDIT VALLEY HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e HOSPITAL FOR SICK CHILDREN   (Canada)

^f PRINCESS MARGARET HOSPITAL   (Canada)

^g MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ANTIGEN PRESENTATION; ARTICLE; ASCITES; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; GENE EXPRESSION; GENE EXPRESSION PROFILING; HIGH GRADE SEROUS OVARIAN CANCER; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; IMMUNE RESPONSE GENE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; OUTCOME ASSESSMENT; OVARY CARCINOMA; OVERALL SURVIVAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TISSUE MICROARRAY; UPREGULATION; AGED; CYSTADENOCARCINOMA, SEROUS; GENE EXPRESSION REGULATION; GENE ONTOLOGY; GENETICS; IMMUNITY; IMMUNOLOGY; METABOLISM; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PATHOLOGY; SURVIVAL; TREATMENT OUTCOME; VERY ELDERLY;

TUMOR PROTEIN;

ADULT; AGED; AGED, 80 AND OVER; ASCITES; CYSTADENOCARCINOMA, SEROUS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE ONTOLOGY; HUMANS; IMMUNITY; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84902196875     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/367103     Document Type: Article

References (31)

1. Sankaranarayanan R., Ferlay J., Worldwide burden of gynaecological cancer: the size of the problem. Best Practice and Research: Clinical Obstetrics and Gynaecology 2006 20 2 207 225 2-s2.0-33644931626 10.1016/j.bpobgyn.2005.10. 007 (Pubitemid 43380597)
2. Birrer M. J., The origin of ovarian cancer-is it getting clearer? The New England Journal of Medicine 2010 363 16 1574 1575 2-s2.0-77957941319 10.1056/NEJMe1009527
3. Karst A. M., Levanon K., Drapkin R., Modeling high-grade serous ovarian carcinogenesis from the fallopian tube. Proceedings of the National Academy of Sciences of the United States of America 2011 108 18 7547 7552 2-s2.0-79956313481 10.1073/pnas.1017300108
4. Tothill R. W., Tinker A. V., George J., Brown R., Fox S. B., Lade S., Johnson D. S., Trivett M. K., Etemadmoghadam D., Locandro B., Traficante N., Fereday S., Hung J. A., Chiew Y.-E., Haviv I., Gertig D., Defazio A., Bowtell D. D. L., Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clinical Cancer Research 2008 14 16 5198 5208 2-s2.0-52649085237 10.1158/1078-0432.CCR-08-0196
5. TCGA, Integrated genomic analyses of ovarian carcinoma. Nature 2011 474 7353 609 615 10.1038/nature10166
6. Yoshihara K., Tsunoda T., Shigemizu D., Fujiwara H., Hatae M., Fujiwara H., Masuzaki H., Katabuchi H., Kawakami Y., Okamoto A., Nogawa T., Matsumura N., Udagawa Y., Saito T., Itamochi H., Takano M., Miyagi E., Sudo T., Ushijima K., Iwase H., Seki H., Terao Y., Enomoto T., Mikami M., Akazawa K., Tsuda H., Moriya T., Tajima A., Inoue I., Tanaka K., High-risk ovarian cancer based on 126-gene expression signature is uniquely characterized by downregulation of antigen presentation pathway. Clinical Cancer Research 2012 18 5 1374 1385 2-s2.0-84863247567 10.1158/1078-0432.CCR-11-2725
7. Shen-Gunther J., Mannel R. S., Ascites as a predictor of ovarian malignancy. Gynecologic Oncology 2002 87 1 77 83 2-s2.0-0036919935 10.1006/gyno.2002.6800 (Pubitemid 36027105)
8. Gerestein C. G., Eijkemans M. J., Bakker J., Elgersma O. E., Van Der Burg M. E. L., Kooi G. S., Burger C. W., Nomogram for suboptimal cytoreduction at primary surgery for advanced sage ovarian cancer. Anticancer Research 2011 31 11 4043 4049 2-s2.0-83055167164
9. Gilani M. M., Karimi Zarchi M., Ghaemmaghami F., Behtash N., Mousavi A. S., Ansaripoor S., A study to evaluate the utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer. Gynecologic Oncology 2007 105 3 780 783 2-s2.0-34248387779 10.1016/j.ygyno.2007.02.027 (Pubitemid 46734210)
10. Tanner E. J., Long K. C., Zhou Q., Brightwell R. M., Gardner G. J., Abu-Rustum N. R., Leitao M. M. Jr., Sonoda Y., Barakat R. R., Iasonos A., Chi D. S., Impact of operative start time on surgical outcomes in patients undergoing primary cytoreduction for advanced ovarian cancer. Gynecologic Oncology 2012 126 1 58 63 2-s2.0-84862769565 10.1016/j.ygyno.2012.04.014
11. Chi D. S., Liao J. B., Leon L. F., Venkatraman E. S., Hensley M. L., Bhaskaran D., Hoskins W. J., Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecologic Oncology 2001 82 3 532 537 2-s2.0-0034823377 10.1006/gyno.2001.6328 (Pubitemid 32826455)
12. Rosenberg S. M., Palliation of malignant ascites. Gastroenterology Clinics of North America 2006 35 1 189 199 2-s2.0-33644817908 10.1016/j.gtc.2005.12.006 (Pubitemid 43356596)
13. Becker G., Blum H. E., VEGF Trap for the treatment of malignant ascites. The Lancet Oncology 2012 13 2 115 116 2-s2.0-84856437873 10.1016/S1470-2045(11) 70394-1
14. Nagy J. A., Masse E. M., Herzberg K. T., Meyers M. S., Yeo K.-T., Yeo-T. K., Sioussat T. M., Dvorak H. F., Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. Cancer Research 1995 55 2 360 368 2-s2.0-0028834106
15. Liao S., Liu J., Lin P., Shi T., Jain R. K., Xu L., TGF- β blockade controls ascites by preventing abnormalization of lymphatic vessels in orthotopic human ovarian carcinoma models. Clinical Cancer Research 2011 17 6 1415 1424 2-s2.0-79952728354 10.1158/1078-0432.CCR-10-2429
16. Kipps E., Tan D. S. P., Kaye S. B., Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nature Reviews Cancer 2013 13 4 273 282 2-s2.0-84875419233 10.1038/nrc3432
17. Sodek K. L., Murphy K. J., Brown T. J., Ringuette M. J., Cell-cell and cell-matrix dynamics in intraperitoneal cancer metastasis. Cancer and Metastasis Reviews 2012 31 1-2 397 414 2-s2.0-84862313384 10.1007/s10555-012-9351-2
18. Eisen M. B., Spellman P. T., Brown P. O., Botstein D., Cluster analysis and display of genome-wide expression patterns. Proceedings of the National Academy of Sciences of the United States of America 1998 95 25 14863 14868 2-s2.0-0032441150 10.1073/pnas.95.25.14863 (Pubitemid 29003722)
19. Smyth G. K., Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Statistical Applications in Genetics and Molecular Biology 2004 3 1, article 3 2-s2.0-4544341015
20. Subramanian A., Tamayo P., Mootha V. K., Mukherjee S., Ebert B. L., Gillette M. A., Paulovich A., Pomeroy S. L., Golub T. R., Lander E. S., Mesirov J. P., Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of Sciences of the United States of America 2005 102 43 15545 15550 2-s2.0-27344435774 10.1073/pnas.0506580102 (Pubitemid 41528093)
21. Soslow R. A., Han G., Park K. J., Garg K., Olvera N., Spriggs D. R., Kauff N. D., Levine D. A., Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma. Modern Pathology 2012 25 4 625 636 2-s2.0-84857555621 10.1038/modpathol.2011.183
22. Sato E., Olson S. H., Ahn J., Bundy B., Nishikawa H., Qian F., Jungbluth A. A., Frosina D., Gnjatic S., Ambrosone C., Kepner J., Odunsi T., Ritter G., Lele S., Chen Y.-T., Ohtani H., Old L. J., Odunsi K., Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America 2005 102 51 18538 18543 2-s2.0-29444442811 10.1073/pnas.0509182102 (Pubitemid 43011261)
23. Leffers N., Gooden M. J. M., De Jong R. A., Hoogeboom B.-N., Ten Hoor K. A., Hollema H., Boezen H. M., Van Der Zee A. G. J., Daemen T., Nijman H. W., Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunology, Immunotherapy 2009 58 3 449 459 2-s2.0-58149303099 10.1007/s00262-008-0583-5
24. Preston C. C., Goode E. L., Hartmann L. C., Kalli K. R., Knutson K. L., Immunity and immune suppression in human ovarian cancer. Immunotherapy 2011 3 4 539 556 2-s2.0-79953811582 10.2217/imt.11.20
25. Zhang L., Conejo-Garcia J. R., Katsaros D., Gimotty P. A., Massobrio M., Regnani G., Makrigiannakis A., Gray H., Schlienger K., Liebman M. N., Rubin S. C., Coukos G., Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. The New England Journal of Medicine 2003 348 3 203 213 2-s2.0-0037448353 10.1056/NEJMoa020177 (Pubitemid 36077915)
26. Clarke B., Tinker A. V., Lee C.-H., Subramanian S., Van De Rijn M., Turbin D., Kalloger S., Han G., Ceballos K., Cadungog M. G., Huntsman D. G., Coukos G., Gilks C. B., Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Modern Pathology 2009 22 3 393 402 2-s2.0-61349151645 10.1038/modpathol.2008.191
27. Callahan M., Nagymanyoki Z., Bonome T., Johnson M. E., Litkouhi B., Sullivan E. H., Hirsch M. S., Matulonis U. A., Liu J., Birrer M. J., Berkowitz R. S., Mok S. C., Increased HLA-DMB expression in the tumor epithelium is associated with increased CTL infiltration and improved prognosis in advanced-stage serous ovarian cancer. Clinical Cancer Research 2008 14 23 7667 7673 2-s2.0-59449090208 10.1158/1078-0432.CCR-08-0479
28. Vitale M., Pelusi G., Taroni B., Gobbi G., Micheloni C., Rezzani R., Donato F., Wang X., Ferrone S., HLA class I antigen down-regulation in primary ovary carcinoma lesions: association with disease stage. Clinical Cancer Research 2005 11 1 67 72 2-s2.0-11344290086 (Pubitemid 40075779)
29. Han L., Fletcher M. S., Urbauer D. L., Mueller P., Landen C. N., Kamat A. A., Lin Y. G., Merritt W. M., Spannuth W. A., Deavers M. T., De Geest K., Gershenson D. M., Lutgendorf S. K., Ferrone S., Sood A. K., HLA class i antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma. Clinical Cancer Research 2008 14 11 3372 3379 2-s2.0-50349084447 10.1158/1078-0432.CCR-07-4433
30. Vergote I., Tropé C. G., Amant F., Kristensen G. B., Ehlen T., Johnson N., Verheijen R. H. M., Van Der Burg M. E. L., Lacave A. J., Panici P. B., Kenter G. G., Casado A., Mendiola C., Coens C., Verleye L., Stuart G. C. E., Pecorelli S., Reed N. S., Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. The New England Journal of Medicine 2010 363 10 943 953 2-s2.0-77956285631 10.1056/NEJMoa0908806
31. Winter W. E. III, Maxwell G. L., Tian C., Carlson J. W., Ozols R. F., Rose P. G., Markman M., Armstrong D. K., Muggia F., McGuire W. P., Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Journal of Clinical Oncology 2007 25 24 3621 3627 2-s2.0-34548491626 10.1200/JCO.2006.10.2517 (Pubitemid 47372600)